TOCOLYTIC THERAPY WITH HEXOPRENALINE IN PREGNANT WOMEN AT RISK FOR PREMATURE BIRTH. THE IMPACT OF ADRB2 GENE POLYMORPHISM ON TOCOLYSIS

Premature birth (PB) is the main cause of mortality and morbidity in newborns without congenital malformations or chromosomal aberrations. Objective: to evaluate the significance of the ADRB2 gene polymorphism in predicting the efficiency and safety of tocolytic pharmacotherapy with β2-adrenostimulants in pregnant women with PB. Subjects and methods. The investigation involved 120 pregnant women, including 60 women at risk for PB who received tocolytic therapy with hexoprenaline as indicated; and 60 ones at no risk for PB. The Gly16Arg and Gln27Glu polymorphisms in the ADRB2 gene were determined in all the study participants. The findings were compared with the indicators of the efficiency and safety of hexoprenaline therapy. Results. The 16Arg allele of the ADRB2 gene was 1.54 times more common in parturients with a normal pregnancy than in patients at risk for PB (the result was insignificant at the accepted significance level, but close to it: χ2=3.8218; p=0.05059). Hexoprenaline therapy prolonged pregnancy to a period of >37 weeks in 65% of the patients with PB. The efficacy of hexoprenaline was lower in the carriers of the genotypes indicating the high or low expression of ß-adrenoreceptors.

ADRB2, obstetrics and gynecology, premature birth, hexoprenaline, genotyping, single nucleotide polymorphisms, ADRB2